Andrew Satlin

Andrew Satlin

Company: Transposon Therapeutics

Job title: Chief Medical Officer


Utilizing Biomarkers to Measure Changes in Neuroinflammation & Neurodegeneration to Validate Safety & Efficacy in ALS Clinical Trials 9:30 am

• Rationale for targeting the LINE-1 reverse transcriptase against ALS and FTD • Exploring biomarkers to measure changes in neuroinflammation and neurodegeneration • Contextualizing biomarker usage for safety and efficacy measurements in phase 2a clinical trialsRead more

day: Day Two AM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.